Meta‐Regression of a Dose‐Response Relationship of Methotrexate in Mono‐ and Combination Therapy in Disease‐Modifying Antirheumatic Drug–Naive Early Rheumatoid Arthritis Patients
Authors:
Open Access
- 19 December 2016
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 69 (10) , 1473-1483
Abstract
Objective: To investigate a possible short‐term dose‐response relationship of initial treatment with methotrexate (MTX) in monotherapy and combination therapy in recent‐onset rheumatoid arthritis (RA) patients.Methods: A systematic literature search was performed on trials and cohorts, including early, disease‐modifying antirheumatic drug (DMARD)–naive RA patients treated with MTX, with data on clinical results within 6 months from treatment start. Cohen's effect sizes were calculated for the Health Assessment Questionnaire (HAQ), erythrocyte sedimentation rate (ESR)/C‐reactive protein (CRP) level, and/or Disease Activity Score (DAS)/in 28 joints (DAS28) in 4 treatment groups: MTX monotherapy, or MTX in combination with synthetic (cs) DMARDs, biologic (b) DMARDs, or glucocorticoids. Random‐effects meta‐regression analyses were performed for each outcome, with treatment group as the predictor corrected for baseline HAQ or disease activity and assessment point.Results: Thirty‐one studies including 5,589 patients were included. The meta‐regression did not support higher effectiveness of increasing MTX dose in monotherapy. The number of treatment groups using combination therapy with csDMARDs was too small to perform meta‐regression analyses. In combination therapy with glucocorticoids, a higher MTX dose was associated with higher (worse) outcome HAQ, but not with DAS/DAS28 or ESR/CRP level. In combination therapy with bDMARDs, a higher MTX dose was associated with higher outcome HAQ and DAS/DAS28, but not with ESR/CRP level. All effect sizes were small.Conclusion: In DMARD‐naive, early RA patients who start MTX, either as monotherapy or in combination with bDMARDs or glucocorticoids, a higher initial dose of MTX was not associated with better clinical outcomes. This finding suggests that there is little short‐term gain from starting with high compared to low MTX doses.Keywords
This publication has 39 references indexed in Scilit:
- Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)Annals of the Rheumatic Diseases, 2013
- Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated studyAnnals of the Rheumatic Diseases, 2013
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- 2009 Updated Method Guidelines for Systematic Reviews in the Cochrane Back Review GroupSpine, 2009
- Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysisAnnals of the Rheumatic Diseases, 2009
- Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E InitiativeAnnals of the Rheumatic Diseases, 2009
- Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature researchAnnals of the Rheumatic Diseases, 2009
- Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literatureAnnals of the Rheumatic Diseases, 2009
- Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)Annals of the Rheumatic Diseases, 2007
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995